NCT00066300: Allogeneic Peripheral Stem Cell Transplantation Followed By Donor Lymphocyte Infusions in Treating Patients With Hematologic Cancer |
|
|
| Active, not recruiting | 2 | | US | graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy | National Heart, Lung, and Blood Institute (NHLBI) | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms | | | | |
NCT00005846: Tipifarnib in Treating Patients With Myeloproliferative Disorders |
|
|
| Active, not recruiting | 1/2 | | US | tipifarnib | Stanford University, National Cancer Institute (NCI) | Leukemia, Myelodysplastic/Myeloproliferative Neoplasms | | | | |
NCT00854841: The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder |
|
|
| Available | N/A | | RoW | Dasatinib and Imatinib, Sprycel and Gliveec | Pusan National University Hospital | Chronic Myeloid Leukemia | | | | |